liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
Pacific Northwest Diabet Research Institute, WA USA .
Le Bonheur Childrens Hospital, TN USA .
Massachusetts Gen Hospital, MA USA .
MacroGenics, MD USA .
Show others and affiliations
2013 (English)In: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 62, no 11, 3901-3908 p.Article in journal (Refereed) Published
Abstract [en]

Protege was a phase 3, randomized, double-blind, parallel, placebo-controlled 2-year study of three intravenous teplizumab dosing regimens, administered daily for 14 days at baseline and again after 26 weeks, in new-onset type 1 diabetes. We sought to determine efficacy and safety of teplizumab immunotherapy at 2 years and to identify characteristics associated with therapeutic response. Of 516 randomized patients, 513 were treated, and 462 completed 2 years of follow-up. Teplizumab (14-day full-dose) reduced the loss of C-peptide mean area under the curve (AUC), a prespecified secondary end point, at 2 years versus placebo. In analyses of prespecified and post hoc subsets at entry, U.S. residents, patients with C-peptide mean AUC andgt;0.2 nmol/L, those randomized 6 weeks after diagnosis, HbA(1c) andlt;7.5% (58 mmol/mol), insulin use andlt;0.4 units/kg/day, and 8-17 years of age each had greater teplizumab-associated C-peptide preservation than their counterparts. Exogenous insulin needs tended to be reduced versus placebo. Antidrug antibodies developed in some patients, without apparent change in drug efficacy. No new safety or tolerability issues were observed during year 2. In summary, anti-CD3 therapy reduced C-peptide loss 2 years after diagnosis using a tolerable dose.

Place, publisher, year, edition, pages
American Diabetes Association , 2013. Vol. 62, no 11, 3901-3908 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-102398DOI: 10.2337/db13-0236ISI: 000326290700033OAI: oai:DiVA.org:liu-102398DiVA: diva2:677371
Note

Funding Agencies|MacroGenics, Inc (Rockville, MD)||Johnson Johnson||Tolerx||MacroGenics||JDRF|2008-502|Le Bonheur Foundation (Memphis, TN)||

Available from: 2013-12-09 Created: 2013-12-09 Last updated: 2017-12-06

Open Access in DiVA

fulltext(1367 kB)158 downloads
File information
File name FULLTEXT01.pdfFile size 1367 kBChecksum SHA-512
0c3e01c04a14cb0c1afb5845ba711ae6290fbfc21f7d872f4be268928d03f16c4581b8b902a892af5a2f2c0e21a0a6d99576abcf529f4b0cf17ad6558492cc58
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Ludvigsson, Johnny

Search in DiVA

By author/editor
Ludvigsson, Johnny
By organisation
Division of Clinical SciencesFaculty of Health SciencesDepartment of Paediatrics in Linköping
In the same journal
Diabetes
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 158 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 152 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf